HWA
BXRX

HCR Wealth Advisors’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

HCR Wealth Advisors’s Portfolio BXRX Stock Details BXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-11
Closed -$15K – 294
2020
Q4 		$15K Buy
+11
New +$22.5K ﹤0.01% 244

Other funds holding BXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

HCR Wealth Advisors's BXRX Position: Q1 2021 in Review

HCR Wealth Advisors sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q1 2021, closing a stake of 11 shares — an estimated $15K sold.

HCR Wealth Advisors first reported a position in BXRX in Q4 2020 and held it in 1 quarter. The position peaked at $15K in Q4 2020. 31 funds tracked by Wall St. Rank hold BXRX as of Q1 2021.

  • HCR Wealth Advisors reported no remaining Baudax Bio, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • HCR Wealth Advisors sold 11 Baudax Bio, Inc. Common Stock shares in Q1 2021, an estimated $15K.
  • HCR Wealth Advisors first reported a position in Baudax Bio, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • HCR Wealth Advisors's Baudax Bio, Inc. Common Stock position peaked at $15K in Q4 2020.
  • 31 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q1 2021.

Based on HCR Wealth Advisors's 13F filing for Q1 2021, filed 13 May 2021.